Publication date: May 23, 2026
Autopsies play a critical role in elucidating the pathogenesis of emerging infectious diseases, particularly in cases involving high-consequence pathogens such as viral haemorrhagic fevers (VHFs). While biosafety concerns have restricted postmortem examinations in such contexts, the COVID-19 pandemic has renewed interest in autopsy-based research and highlighted both the potential and the gaps in current biosafety protocols. This narrative review outlines autopsy practices in the context of high-consequence infectious diseases (HCIDs) with a focus on VHFs, summarizes reported autopsy cases, explores alternative postmortem methods and examines the evolution of legal and institutional frameworks in response to the pandemic. A comparison of official international guidelines shows that while detailed autopsy protocols have been published for pathogens requiring BSL-3 containment – particularly in the United States (US) and United Kingdom (UK) – no official procedural guidance seem to be available for performing autopsies under BSL-4 conditions. Instead, current recommendations at this level are limited to postmortem handling and disposal of the deceased. This regulatory and procedural gap underscores the urgent need for harmonized, high-containment autopsy protocols that balance biosafety with scientific value. Developing such frameworks will be essential to improve outbreak preparedness and enabling evidence-based responses to future pandemics globally. Accordingly, we propose a structured, system-based approach to BSL-4 autopsy practice as a foundation for discussion and future guideline development.

Open Access PDF
| Concepts | Keywords |
|---|---|
| Autopsy | autopsy |
| Future | biosafety level 4 |
| Microbes | forensic pathology |
| Pandemic | postmortem procedures |
| Viral | viral haemorrhagic fevers |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | infectious diseases |
| disease | MESH | emerging infectious diseases |
| disease | MESH | fevers |
| disease | MESH | COVID-19 pandemic |
| drug | DRUGBANK | Isoxaflutole |